中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2015年
1期
26-26,27
,共2页
难治性心力衰竭%重组人脑利钠肽%心力衰竭
難治性心力衰竭%重組人腦利鈉肽%心力衰竭
난치성심력쇠갈%중조인뇌리납태%심력쇠갈
Refractory heart failure%Recombinant Human Brain Natriuretic Peptide%Heart failure
目的:观察重组人脑利钠肽治疗难治性心力衰竭的临床疗效和安全性。方法:选取130例难治性心力衰竭患者按照随机数字表法分为重组人脑利钠肽治疗组(观察组)和硝酸甘油治疗组(对照组),每组65例,两组患者均给予相同基础治疗,观察两组患者心功能改善情况、疗效及不良反应发生情况。结果:观察组治疗后左室舒张末期内径(LVEDD)小于对照组,左心室射血分数(LVEF)高于对照组(P<0.05);观察组治疗总有效率为92.30%,高于对照组的67.69%(P<0.05);两组患者低钾血症、心律失常、恶心等不良反应发生情况比较,差异无统计学意义(P>0.05)。结论:重组人脑利钠肽治疗难治性心力衰竭安全性好,疗效优于硝酸甘油。
目的:觀察重組人腦利鈉肽治療難治性心力衰竭的臨床療效和安全性。方法:選取130例難治性心力衰竭患者按照隨機數字錶法分為重組人腦利鈉肽治療組(觀察組)和硝痠甘油治療組(對照組),每組65例,兩組患者均給予相同基礎治療,觀察兩組患者心功能改善情況、療效及不良反應髮生情況。結果:觀察組治療後左室舒張末期內徑(LVEDD)小于對照組,左心室射血分數(LVEF)高于對照組(P<0.05);觀察組治療總有效率為92.30%,高于對照組的67.69%(P<0.05);兩組患者低鉀血癥、心律失常、噁心等不良反應髮生情況比較,差異無統計學意義(P>0.05)。結論:重組人腦利鈉肽治療難治性心力衰竭安全性好,療效優于硝痠甘油。
목적:관찰중조인뇌리납태치료난치성심력쇠갈적림상료효화안전성。방법:선취130례난치성심력쇠갈환자안조수궤수자표법분위중조인뇌리납태치료조(관찰조)화초산감유치료조(대조조),매조65례,량조환자균급여상동기출치료,관찰량조환자심공능개선정황、료효급불량반응발생정황。결과:관찰조치료후좌실서장말기내경(LVEDD)소우대조조,좌심실사혈분수(LVEF)고우대조조(P<0.05);관찰조치료총유효솔위92.30%,고우대조조적67.69%(P<0.05);량조환자저갑혈증、심률실상、악심등불량반응발생정황비교,차이무통계학의의(P>0.05)。결론:중조인뇌리납태치료난치성심력쇠갈안전성호,료효우우초산감유。
Objective:To investigate the clinical efficacy and safety of Recombinant Human Brain Natriuretic Peptide in the treatment of refractory heart failure.Method:130 patients with refractory heart failure were randomly divided into Recombinant Human Brain Natriuretic Peptide treatment group(the observation group) and Nitroglycerin treatment group(the control group).Both groups were provided equally basic treatment,to observe two groups of patients’ cardiac function improved and the occurrence of adverse reactions.Result:Upon treatment,left ventricular diastolic diameter(LVEDD) of the observation group was smaller than the control group,and left ventricular ejection fraction(LVEF) was higher than that of the control group(P<0.05).The total treatment effective rate of the observation group was 92.30%,was higher than 67.69%of the control group(P<0.05).The hypokalemia,cardiac arrhythmias,nausea and other side-effect reactions of the observation group compared with the control group,there was not statistically significant(P>0.05).Conclusion:The treatment of Recombinant Human Brain Natriuretic Peptide on patients with refractory heart failure is with safety and therapeutic effect is superior to Nitroglycerin.